Premium
Tolerability and efficacy of house dust mite AIT
Author(s) -
Mosbech H.
Publication year - 2011
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.2011.02641.x
Subject(s) - tolerability , medicine , asthma , house dust mite , allergy , placebo , pyroglyphidae , clinical endpoint , adverse effect , randomized controlled trial , anesthesia , immunology , allergen , alternative medicine , pathology
To cite this article: Mosbech H. Tolerability and efficacy of house dust mite AIT. Allergy 2011; 66 (Suppl. 95): 55–56. Abstract Sublingual immunotherapy based on grass pollen allergy immunotherapy tablets is an efficacious and well‐tolerated treatment for rhinoconjunctivitis, and subcutaneous house dust mite (HDM) immunotherapy is effective against allergic asthma. Three studies have investigated a new ALK tablet for HDM allergy: two studies on tolerability in adults and children, and one on efficacy and safety in adults and adolescents with asthma. Treatment was well tolerated, mainly with mild‐to‐moderate local reactions pertaining to the administration site, such as temporary oral pruritus. The primary efficacy endpoint was a significant reduction in inhaled corticosteroid dose compared to baseline after 1 year of daily treatment. A positive therapeutic effect on asthma was demonstrated by a reduction of more than 80 μg/day inhaled budesonide for a group receiving six developmental units daily compared to the placebo group.